| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 |
8-K: Results of Operations and Financial Condition
FDA lifted clinical hold on ARD-101 for the treatment of hyperphagia in Prader-Willi Syndrome (PWS) |
| 13 Nov 2026 | 10-Q |
| 10 Nov 2026 |
Form 4: Lee Tien-Li, Director
Granted 793,951 Stock Option (right to buy) · Disposed of 793,951 Stock Option (right to buy) (Disposition to Issuer) |
| 10 Nov 2026 |
Form 4: Sun Nelson, See Remarks
Granted 304,094 Stock Option (right to buy) · Disposed of 304,094 Stock Option (right to buy) (Disposition to Issuer) |
| 10 Nov 2026 |
Form 4: Jaiman Manasi, Chief Medical Officer
Granted 374,560 Stock Option (right to buy) · Disposed of 374,560 Stock Option (right to buy) (Disposition to Issuer) |
| 23 Oct 2026 |
8-K: Other Events
Disclaimer Aardvark Therapeutics, Inc. (“we”, “us,” “our” or the “Company”) does not (nor its respective affiliates, directors, members, officers, employees or agents) make any representation or warranty, express or implied, as to, and n... |
| 22 Oct 2026 |
8-K: Other Events
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data |
| 08 Oct 2026 |
Form 4: Zhang Zhongwei, Director
Granted 127,061 Stock Option (right to buy) |
| 08 Oct 2026 |
Form 3: Zhang Zhongwei, Director
No securities owned |
| 08 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Brings more than 25 years of experience in clinical strategy, biostatistics and regulatory submissions from Abivax, Alumis, MyoKardia and Genentech/Roche |
| 11 Sep 2026 |
Form 4: Sun Nelson, See Remarks
Sold 14,754 shares ($73.8K) · Sold 62,000 shares ($321K) |
| 11 Sep 2026 | 144 |
| 10 Sep 2026 | 144 |
| 21 Aug 2026 |
Form 4: Chi Jeffrey, Director
Granted 44,964 Stock Option (right to buy) |
| 21 Aug 2026 |
Form 4: Graf Susan E, Director
Granted 44,964 Stock Option (right to buy) |
| 21 Aug 2026 |
Form 4: Baynes Roy D., Director
Granted 44,964 Stock Option (right to buy) |
| 21 Aug 2026 |
Form 4: Tong Victor Edward Jr, Director
Granted 44,964 Stock Option (right to buy) |
| 17 Aug 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On August 14, 2026, Aardvark Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 21,884,158 shares of the Company’s common stock outstanding as of June 18, 2026, the record date ... |
| 11 Aug 2026 | 10-Q |
Loading...